Entered into an exclusive license agreement with Dynavax for the Company’s COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback